Maxim Group Lowers ContraVir Pharmaceuticals (CTRV) to Hold

ContraVir Pharmaceuticals (NASDAQ:CTRV) was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating in a research report issued on Tuesday, MarketBeat reports.

Separately, ValuEngine upgraded ContraVir Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

ContraVir Pharmaceuticals (NASDAQ CTRV) opened at $0.26 on Tuesday. ContraVir Pharmaceuticals has a 52 week low of $0.23 and a 52 week high of $1.96.

An institutional investor recently bought a new position in ContraVir Pharmaceuticals stock. Anson Funds Management LP purchased a new stake in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,237,957 shares of the biopharmaceutical company’s stock, valued at approximately $446,000. ContraVir Pharmaceuticals makes up 0.3% of Anson Funds Management LP’s investment portfolio, making the stock its 26th largest holding. Anson Funds Management LP owned about 1.57% of ContraVir Pharmaceuticals as of its most recent filing with the SEC. Hedge funds and other institutional investors own 6.71% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2018/02/15/maxim-group-lowers-contravir-pharmaceuticals-ctrv-to-hold.html.

ContraVir Pharmaceuticals Company Profile

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply